Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
04:12p Special Report - In Venezuela's murky oil industry, the deal that went too far
04:12p DIAMONDCORP : Says Underground Mining Operations Resumed At Lace Mine
04:12pDJMARKET SNAPSHOT : Stocks Muster Modest Rise As Tech Climbs
04:12p TRANSENTERIX INC : DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against TransEntrix, Inc. (TRXC) and Lead Plaintiff Deadline: August 1, 2016
04:11p ITT EDUCATIONAL SERVICES : Most of the Nation's Drafting Graduates Attended ITT Technical Institute
04:11p GENERAL MILLS : SDSU Partner for Oats Research
04:11p AUDAX PRIVATE EQUITY : Announces the Acquisition of RelaDyne, Inc.
04:11pDJBT : Rejects Regulator's Call for Legal Separation of Network Business -- Update
04:10p CINEPLEX : Opening New Theatre in North Barrie This Week
04:10p EMBASSY OF UNITED STATES OTTAWA CANADA : Anniversary of the Americans with Disabilities Act
Latest news
Advertisement
Hot News 
-3.59%ORANGE : Gets Profit Boost From EE Sale
-4.50%COMMERZBANK : Oil Prices Down on Growing Concerns About Oversupply
4.25%BT avoids break-up with plan to run network arm separately
-6.45%Man Group's funds fall in first half, Brexit yet to hit flows
-1.89%MAN GROUP PLC MAN GROUP PLC : Form 8.3 - Sainsbury (J) Plc
Most Read News
07/25 MainOne, Radware Lead Fight Against Cyber Threats with DDoS Solution
Most recommended articles
10:09aDJENI : 2Q 2016 -- Forecast
10:06a HSBC : Swiss to pass information on HSBC accounts to U.S. tax agency
10:06a Wall Street little changed as investors assess earnings
10:03aDJOil Workers Strike Over Shell's Proposed Cuts
10:02a BT avoids break-up with plan to run network arm separately